alexa
Reach Us +44-1647-403003
Emerging Systemic Therapeutic Approaches for Personalized Medicine in Squamous Cell Carcinoma of the Lung | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

Emerging Systemic Therapeutic Approaches for Personalized Medicine in Squamous Cell Carcinoma of the Lung

Grace Kho Dy*
Department of Medicine, Roswell Park Cancer Institute, USA
Corresponding Author : Grace Kho Dy, MD
Department of Medicine
Roswell Park Cancer Institute
Buffalo, NY, USA
E-mail: [email protected]
Received March 01, 2012; Accepted March 21, 2012; Published March 23, 2012
Citation: Dy GK (2012) Emerging Systemic Therapeutic Approaches for Personalized Medicine in Squamous Cell Carcinoma of the Lung. J Cancer Sci Ther S11:003. doi: 10.4172/1948-5956.S11-003
Copyright: © 2012 Dy GK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Abstract

During the past decade, a number of novel agents developed for the treatment of advanced NSCLC had, by coincidence, shown survival benefit predominantly among patients with nonsquamous histology, namely pemetrexed (anti-folate), bevacizumab (VEGF pathway inhibition), erlotinib/gefitinib (EGFR receptor tyrosine kinase inhibitors) and crizotinib (ALK receptor tyrosine kinase inhibitor. This has sparked a heightened interest in discovering key molecular aberrations that may be relevant for the treatment of squamous cell carcinoma (SCC) of the lung, a histologic subtype that represents approximately 25% of lung cancer cases diagnosed globally. This article highlights the most promising recent discoveries and targeted agents in development that may be relevant for the treatment of SCC of the lung.

Share This Page
Top